Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 62331-055; 67317-0001; 67651-0275; 70600-028; 50473-0001; 67317-0031; 65977-0129; 67651-0276; 65015-841; 67651-0274
UNII 43Y000U234
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Body temperature increased13.15.01.001--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.009--Not Available
Carpal tunnel syndrome17.09.02.001--Not Available
Cerebellar ataxia17.02.02.013; 08.01.02.006--Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Cyst16.02.02.002; 08.03.05.001--Not Available
Delirium19.13.02.001--
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.004--Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 9 Pages